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Abstract 
Background: Malaria transmission in The Gambia decreased substantially over the last 20 years thanks to the scale‑
up of control interventions. However, malaria prevalence is still relatively high in eastern Gambia and represents both 
a health and a financial burden for households. This study aims to quantify the out‑of‑pocket costs and productivity 
losses of seeking malaria treatment at household level.
Methods: A household survey was carried out through in‑person interviews. Respondents were asked about malaria 
prevention methods, their treatment‑seeking behaviour, and any costs incurred for transport, services, food, and/or 
overnight stays. A bottom‑up costing approach was used to calculate the unit cost of treatment and a tobit regres‑
sion approach to investigate cost drivers.
Results: The survey included 864 respondents, mainly subsistence farmers. Most respondents (87%) considered 
malaria to be a problem affecting their ability to perform their regular duties. Respondents preferred going to a health 
facility for treatment. The primary reason for not going was related to costs; 70% of respondents incurred costs for 
seeking health care, with a median of £3.62 (IQR: £1.73 to £6.10). The primary driver of cost was living in one of the 
villages that are off the main road and/or far from health facilities. 66% reported productivity loss of 5 working days on 
average during a malaria episode of them or their child.
Conclusions: Although malaria prevalence is decreasing and treatment is provided free of charge, households seek‑
ing treatment are confronted with out‑of‑pocket expenditures and lost working days; particularly in remote villages.
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licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
In 2017, the estimated global burden of malaria was 
219  million cases and 435,000 deaths [1], 90% of which 
occurring in sub-Saharan Africa [2]. The Gambia, a small 
country in western Africa, has been very successful in 
decreasing the malaria burden: clinical malaria incidence 
has dropped fivefold, from 275 cases per 1000 popula-
tion in 2010 to 57 cases per 1000 population in 2017. This 
has been achieved thanks to the scale-up by the National 
Malaria Control Programme (NMCP) of malaria control 
interventions, such as insecticide-treated nets, indoor 
residual spraying (IRS), intermittent preventative treat-
ment during pregnancy, and seasonal malaria chemopre-
vention (SMC). Nevertheless, malaria transmission is still 
ongoing, particularly in eastern Gambia, in the Upper 
River Region (URR) [3]. Asymptomatic malaria cases 
are often mentioned as the reservoirs for this continued 
transmission and novel strategies are needed to clear 
these [2–4].
Several trials are currently underway to investigate 
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drug administration (MDA) based on the endectocidal 
drug ivermectin (IVM) [4–6]. To evaluate adoption of 
such an approach by national or global stakeholders, it is 
important that its cost-effectiveness is established. Cost-
ing studies are an essential component of cost-effective-
ness analyses [7, 8]. Although various types of costing 
studies are needed, household costs are a particularly 
important type of costing study because apart from a 
health impact, malaria also has a financial impact on 
households because they incur costs for prevention and 
for case management. Malaria diagnosis and treatment in 
The Gambia, as in many other sub-Saharan African coun-
tries, is provided free of charge, but indirect costs can 
still be incurred. Studies from Ghana, Kenya and Ethiopia 
show that households incur costs for transport, food, and 
overnight stays in health facilities [9–11]. Unfortunately, 
household costing data are not available for The Gambia. 
The aim of this study is to fill this knowledge gap by sur-
veying households in URR about their malaria treatment-
seeking behaviour and the (in)direct costs they incur 
whilst doing so.
Methods
Study setting and respondent selection
This study was part of a larger village-level, cluster-
randomized trial evaluating the efficacy of MDA with 
IVM and the anti-malarial drug dihydroartemisinin-
piperaquine (DP) on residual malaria transmission 
(#NCT03576313). The trial started in September–Octo-
ber 2018 and included 32 medium-sized villages (16 con-
trol and 16 intervention) in the southern bank part of the 
URR. As part of the RCT, a quantitative survey on the 
acceptability of MDA and the (costs of ) seeking care was 
carried out. The sample size was designed to substanti-
ate inferences concerning trial participation, defined as 
a multinomial outcome with three levels: no participa-
tion, partial participation, full participation. Assuming an 
effect size of 1.5, an intra-correlation of 1 and 80% power, 
the required sample size was estimated at 850 individuals 
(aged above 12), rounded up to 900, in the 16 interven-
tion villages. The target sample size per village was made 
proportional to the village population size. Participants 
were randomly selected from the most recent census data 
collected by the trial field team; individuals absent or 
refusing to participate were replaced by others of similar 
age and gender. In addition to the household survey, vil-
lage health workers (VHWs) of trial intervention villages 
were interviewed. The aim was to include all 16 interven-
tion villages.
Data collection
The survey was carried out between January and Febru-
ary of 2019, 2–3 months after the first intervention year. 
Part of the acceptability survey concerned treatment-
seeking behaviour and costs. These questions were 
developed based on the ACT Consortium guidance [12]. 
Respondents, besides demographic information, gen-
eral malaria knowledge, owned means of transport, and 
primary economic activities; were asked questions on 
their treatment-seeking behaviour for malaria, malaria 
prevention methods employed, and perceived problems 
associated with malaria. Information on the last episode 
of malaria experienced by them and by one child of the 
household was also collected, including the preferred and 
chosen treatment option and costs incurred. Questions 
and potential responses of non-economic topics were 
formulated on the basis of qualitative and ethnographic 
data collected prior to and during the implementation of 
the MDA in 2018. Data were electronically captured in 
Epi Info v.7 by trained field workers using Android tab-
lets. Data were synced at the end of every field day and 
checked for quality.
The interviews with VHWs of trial intervention villages 
were conducted during the summer of 2019. They were 
asked questions about their background as well as their 
role in malaria testing and treatment. In addition, they 
were asked about barriers surrounding malaria testing 
and treatment facing them as well as the inhabitants of 
their village.
Analysis of costing data
A bottom-up costing approach was used to calculate the 
unit costs incurred by a household of the last malaria epi-
sode for an adult and for a child. Direct cost components 
were defined as costs for testing and treatment while 
indirect costs were defined as costs of transport, costs of 
overnight stays and related food. Uncomplicated cases 
were assumed to not incur costs for overnight stays or 
food. All costs were obtained directly from the respond-
ents. Productivity losses were measured in number of 
working days missed, either to obtain one’s own treat-
ment or to accompany a sick child to a health facility. The 
total financial impact of malaria care-seeking on house-
holds in URR was calculated by multiplying the unit cost 
of seeking care by the average yearly clinical incidence of 
malaria based on data obtained from the NMCP.
Costs are reported in 1 January 2020 British pounds, 
using the average Gambian Dalasi to British Pound 
exchange rate during the period October–Novem-
ber 2018 (about 61 Dalasi per 1 GBP). This is the peak 
malaria season when malaria-related costs would have 
been incurred.
To investigate what demographic variables drive the 
household unit cost of obtaining malaria treatment, a 
tobit regression approach was applied [13]. This approach 
is particularly well-suited for costing data where a 
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proportion of the sample may have zero costs, leading to 
highly skewed data.
Ethics
All participants (and their guardians if under 18) were 
explained the purpose of the study by trained field staff 
in their preferred language prior to giving informed con-
sent and/or assent (minors) to participate. The study was 
approved by the Institutional Review Boards of the Insti-
tute of Tropical Medicine Antwerp and by the Gambian 
Government/MRC Joint Ethics Committee.
Results
The household survey was completed by 864 respond-
ents, 66% of them women. The median age was 29 years 
(IQR: 19–41). Fulas were the most represented ethnic 
group (73%) and most respondents (80%) were subsist-
ence farmers. A large proportion of respondents (41%) 
had not received any formal education (Table 1). In total, 
14 VHWs were interviewed. Most had received a 4-week 
training on testing and treating Malaria in Basse (the 
major town in URR) and they had 5 years’ worth of expe-
rience on average.
Perspectives on malaria and healthcare‑seeking behaviour
A large proportion of respondents (63%) considered malaria 
a relevant, but declining problem, while 25% had the oppo-
site view and considered malaria as a current problem. This 
view was shared by VHWs, of whom 79% indicated malaria 
was a problem in their village. When asked what non-health 
problems malaria can cause for the patient or their family, 
65% stated missing work, 56% missing household respon-
sibilities, and 50% missing school. Malaria was indicated to 
cause financial problems due to costs incurred at the health 
facility (42%), for medicines (46%), or for transport (37%).
The belief that malaria can be prevented by using 
bed nets was shared by 95% of participants. In addi-
tion, almost half of respondents (45%) believed malaria 
could be prevented by cleaning the environment. Fewer 
believed malaria could be prevented using sprays (20%), 
coils (11%), medication (6%), or herbs (13%). Regarding 
treatment, 85% of respondents believed malaria medica-
tion should be taken even if someone was no longer vis-
ibly sick. VHWs indicated that the majority of people in 
their villages used bed nets (33%), environmental clean-
ing (21%), or coils (16%) to prevent malaria. All VHWs 
indicated that NMCP prevention activities (bed net 
campaign, IRS, SMC) had taken placed in their village in 
2019. Most VHWs had a role in IRS and SMC (> 80%), 
but this was less so for net distribution (57%).
Malaria in the previous months was reported by 28% 
of adults; 37% of them reported an episode of malaria 
among children of their household. All but one VHWs 
indicated that most villagers with fever came to them first 
to seek testing and/or treatment. Despite this, the large 
majority of episodes in adults (89%) and children (91%) 
reported preferring and having received treatment at a 
health facility. Very few adults self-treated (4%), received 
treatment by VHWs (4%), or by a traditional healer (1%). 
Similarly, most children (91%) were treated at a health 
facility. Overall, most respondents went to the centrally 
located—and largest—facility in Basse, despite not being 
the closest one for many respondents (Fig. 1).
Most respondents travelled to the health facility using 
public transport (36%), followed by motorcycle (24%), 
walking (12%), or donkey cart (8%). Private or MRC-
provided transport were rarely used (1% and < 1%, 
respectively). 15% of respondents used a combination of 
transport modes. The choice of transport was not dif-
ferent between adult cases versus paediatric cases. The 
mean distance to the chosen health facility was 37  km 
(95% CI 12 to 48).
Barriers to preventing malaria and seeking care
Not getting/having enough bed nets (50%) and finan-
cial difficulties (29%) were mentioned by VHWs as most 
important prevention challenges, followed by a lack of 
cleaning materials (21%) or coils (14%). The 59 respond-
ents who indicated that they did not go to the health 
facility for the most recent malaria episode gave as rea-
sons: transport costs (17%), service costs (12%), or that 
they were treated at home (10%). All VHWs indicated 
that a lack of supplies prevented them from consistently 
testing and treating malaria as per their training and 
the village’s needs. Barriers to accessing care for villag-
ers according to VHWs were the unavailability of RDTs 
(86%) and anti-malarial drugs (93%) at the village level. 
Although a majority (86%) of VHWs indicated that the 
coordination between them and the health facilities was 
good, 64% of them also stated that having to travel to the 
health facility presented a barrier to accessing malaria 
care for people in their village.
Cost of seeking treatment at a health facility
More than half (54%) of respondents who attended a 
health facility incurred out-of-pocket expenditures for 
transport, with a median cost of £1.07 (IQR: £0.66 to 
£1.65). When at the health facility, 65% had to pay for 
services, to the median amount of £3.30 (IQR: £1.65 to 
£4.94). Only 6% of respondents had to pay for food dur-
ing the visit to the health facility; the median amount 
paid was £4.37 (IQR: £1.65 to £5.15). When combined, 
70% of respondents incurred out-of-pocket expenses 
when attending a health facility, the median of which 
was £3.62 (IQR: £1.73 to £6.10). Regarding productivity 
losses, 56% of respondents indicated productive work 
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Table.1 Demographics of the respondent population and results from the multivariate tobit regression against total costs in 2020 
GBP
IQR interquartile range
† Intercepts of model had as estimates 262.64 and 5.30 with standard errors of 68.05 and 0.03; both had p-values < 0.01
‡ Standard education was defined as having enjoyed primary, junior, senior, and/or more than senior education
Asterisks denote significance level: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
Descriptive statistics Multivariate tobit  regression†
N = 864 Median (IQR) Coefficient Standard error p‑value
Age 29 (19–41) − 0.33 0.78 0.67
n (%)
Gender = female 566 (65.8) − 42.55 29.07 0.143
Village
 Sare Njobo 86 (10.0) − 33.54 41.99 0.424
 Sare Banico Gimara 29 (3.4) 63.78 54.42 0.241
 Sare Cherno 41 (4.8) − 118.19 54.29 0.029*
 Jalali Kunda 36 (4.2) 12.53 57.31 0.827
 Sare Jallow 40 (4.6) − 88.37 50.77 0.082
 Giroba 112 (13.0) Reference level
 Sare Yoro Checky 36 (4.2) − 34.61 53.15 0.515
 Keneba 60 (7.0) 17.45 44.62 0.696
 Sare Garba 38 (4.4) 184.35 49.31 0.000***
 Koli Kunda 75 (8.7) 122.43 40.85 0.003**
 Ceesay Kunda 54 (6.3) 79.82 43.88 0.069
 Karantaba 38 (4.4) 66.91 47.19 0.156
 Darsilameh Julah 35 (4.1) 175.12 54.09 0.001***
 Sare Gela 70 (8.1) 92.36 42.77 0.031*
 Sami Kuta 70 (8.1) 2.38 44.95 0.958
 Sare Biru 43 (5.0) 16.82 49.43 0.734
Status
 Compound head 69 (8.0) Reference level
 Household head 24 (2.8) − 8.54 68.70 0.901
 Compound member 226 (26.2) − 56.73 39.24 0.148
 Wife 360 (41.7) − 4.54 44.99 0.920
 Child 182 (21.1) − 69.01 49.36 0.162
 Other 2 (0.2) − 122.17 217.87 0.575
Education
 None 357 (41.1) Reference level
  Standard‡ 243 (28.2) − 23.34 25.07 0.352
 Quranic 261 (30.2) − 63.13 21.95 0.004**
 Other 2 (0.2) − 154.83 155.49 0.319
Ethnic group Not included in regression
 Fula 626 (72.5)
 Mandinka 172 (19.9)
 Sarahule 56 (6.5)
 Other 9 (1.0)
Primary economic activity
 Farming 694 (80.3) − 3.07 29.65 0.918
 Herding 65 (7.5) − 7.99 36.19 0.825
 Business 131 (15.2) 70.76 25.81 0.006**
 Domestic 263 (30.0) − 10.21 20.26 0.614
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lost during their last malarial episode and 39% indicated 
productive work lost during the last episode of their 
child. In both cases, 5 working days were lost on average 
by the adult (IQR: 4 to 7).
The total expected expenditures by households in URR 
on malaria treatment ranged from £44,293 in 2017 to 
£164,288 in 2015 (Table  2). Of these costs, 97% would 
be for uncomplicated cases. Total expected expenditures 
were calculated by multiplying the out-of-pocket cost 
estimates for seeking care with the historical clinical inci-
dence (of both uncomplicated and complicated malaria), 
as reported by NMCP.
Drivers of costs
Overall, services constituted the majority of costs (69%) 
followed by transport (22%) and overnight stays/food 
(9%). Median costs were higher for adults (£4.20, IQR: 
£2.02 to £6.70) than for children (£3.54, IQR: £0.41 to 
£6.18). The average out-of-pocket cost incurred for ser-
vices differed by the choice of the health provider; it was 
the highest for a health facility (£3.91), followed by home 
treatment (£3.21), village health worker (£2.73), tradi-
tional healer (£2.06) or MRC (£2.04). Travelling by pub-
lic transport to attend a health facility costed an average 
amount of £1.34 out-of-pocket. This was slightly less for 
those who travelled by motorbike (£1.21), donkey cart 
(£0.33), or walking (£0.03). Transport expenditures for 










































Fig. 1 Map of the Upper River Region in the Gambia showing the health facilities visited for malaria treatment by survey respondents. The width of 
lines is proportional to the number of respondents from a particular that indicated having gone to a particular health facility
Table.2 Estimation of total costs incurred by households in URR 
during the years 2013–2017 based on this study and malaria 
clinical incidence data in URR for these years obtained from the 





Household costs for 
seeking treatment
2013 1515 45,479 £145,021
2014 933 26,806 £85,613
2015 1273 52,007 £164,288
2016 1262 34,167 £109,368
2017 526 13,821 £44,293
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For the tobit regression analysis, the demographic 
variables in Table  1  were included, with the exception 
of ethnic group as this is highly correlated with village 
of residence (most villages are composed predomi-
nantly of one ethnic group). The cost of seeking malaria 
care is reduced significantly by having a Quranic as 
opposed to no education (p < 0.01) and having business 
among one’s primary economic activities (p < 0.01). 
Compared to the largest village of Giroba (Fig. 2), peo-
ple from some villages (Sare Garba, Koli Kunda, Dar-
silameh Julah or Sare Gela) bear a significantly higher 
total cost (p < 0.01), while villagers from Sare Cherno 
had a significantly lower cost (p = 0.03). Age, status in 
household, and owning particular modes of transport 
did not significantly impact the total costs of seeking 
malaria treatment.
Discussion
This study investigated treatment-seeking behaviour 
and expenditures incurred by households in URR, The 
Gambia, when one of their members contracts malaria. 
The results show that most respondents considered 
malaria a problem that affects their quality of life and 
their economic productivity. Although in The Gam-
bia malaria treatment is free of charge, many barriers 
to this actually happening are mentioned. Seventy per 
cent of respondents reported incurring expenditures 
for malaria treatment. The health facility is seen as 
the most efficient way to treat malaria and households 
incurred a median of £3.72 in out-of-pocket expenses 
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Fig. 2 Map of the Upper River Region showing median household costs for seeking malaria care during the last transmission season per village as 
indicated by survey respondents
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The primary cost driver in this study is village of resi-
dence. This is not surprising given the fact that the vil-
lages where respondents incurred significantly more 
costs are located between the health facilities surround-
ing Basse and the health facilities at the eastern tip of 
URR (Fig.  2). Furthermore, they are off the main west-
east road and/or have a road connection that is in bad 
condition (especially during the rainy season). Village 
of residence was, in this study, a pragmatic surrogate 
for travel time because travel times are hard to calculate 
given the many modes of transport people employ and 
the varying condition of roads throughout the year. That 
travel time (or distance to health facility) is an important 
driver of costs is also found in earlier malaria treatment 
costing studies in Ghana, Ethiopia, Malawi, and Uganda 
[9, 11, 14, 15]. What is different is that in this study costs 
for services constituted nearly two-thirds of total costs, 
while in the other studies it was the reverse. Based on 
earlier qualitative fieldwork in the region, the VHW 
interviews, and an earlier study in the west of The Gam-
bia [16], it could be hypothesized that the relatively high 
expenditure on services is due to regular stock-outs at 
health facilities that require people to purchase treatment 
at private pharmacies in the larger towns. This is a cause 
of frustration for VHWs who despite being trained to test 
and treat (uncomplicated) malaria, are often not able to 
do so because of a lack of RDTs and anti-malarial drugs. 
The majority of transport and services costs incurred 
by households for seeking malaria treatment could be 
avoided if people could consistently receive treatment 
locally in their own village. This would require more sup-
plies and better distribution according to need.
Other drivers of treatment-seeking costs found in the 
literature are relative household wealth, public versus pri-
vate facility, and availability of drugs at the health facility. 
In this study data on household wealth was not collected, 
but it is reasonable to postulate that involvement in busi-
ness and educational level (which significantly affects 
total cost in this study’s sample) are proxies for house-
hold wealth. In addition, given the social structure in the 
Gambia, it is reasonable to assume that healthcare costs 
are shared by members of a household or a compound. 
This may mean that, although this study’s results did not 
show being a household or compound head has a sig-
nificantly effect on costs, actual malaria-related costs for 
these people may be higher as they are expected to pay 
for the care of others under their care as well. The survey 
did not include questions specifically about if respond-
ents went to a public or private health facility because 
there are almost no private clinics in URR and data on 
stock-outs at health facilities is not available. However, 
the relatively high costs of services in a system that 
should in theory provide malaria care for free could be a 
reflection of the fact that a part of treatment (drug provi-
sion) is being taken up by private pharmacies.
A major strength of this study is the large sample of 
respondents across URR and the inclusion of the VHW 
perspective. This provides confidence in the reliability 
of the results. The primary limitation of this study is the 
cross-sectional approach and the reliance on respond-
ent call-back. Despite practical and financial barriers, 
the majority of respondents reported seeking biomedi-
cal treatment for malaria at a health facility. This is in line 
with earlier research in The Gambia [16, 17], but there are 
two limitations that put these findings into perspective 
[17]. First of all, there can be an overlap between (symp-
toms of ) malaria and certain folk illnesses. Secondly, 
some symptoms of malaria can be perceived to have 
supernatural causes. The treatment-seeking behaviour 
for folk illnesses and supernatural afflictions are differ-
ent than those for malaria, even though a malaria infec-
tion may be a cause for both of them. These factors may 
have led to an overestimation of health facility prefer-
ence and an underestimation of the total malaria-related 
cost impact on URR. Relying on respondent recall may 
also have biased the costing results as respondents may 
not remember correctly what was spent a few months 
before the interview. There was no question that asked 
them about when the latest malaria episode occurred, 
which made it is hard to assess the impact of the recall 
bias on the results. A related limitation is that this sur-
vey was administered in between year 1 and year 2 of the 
MASSIV trial. Potential benefits derived from access to 
the study medicines could have added a desirability bias 
to participants’ responses. Another limitation is costs 
incurred for severe malaria. As this is relatively rare and 
is sometimes fatal, it is likely that the results of this study 
mainly reflect costs incurred for uncomplicated malaria. 
Finally, because this focused on out-of-pocket expendi-
tures, the results primarily reflect financial rather than 
economics costs. Data was in fact collect data on work-
ing days lost, but converting this to a monetary value was 
not practical, as 80% of the respondents were subsist-
ence farmers and thus had no formal income. There are 
methods for assessing wealth of subsistence farmers, but 
they are time-intensive and would have carried the risk of 
respondent fatigue in an already long survey.
Conclusions
The residual transmission of malaria in The Gambia’s 
URR region requires households to keep spending money 
on prevention and treatment. This study has quanti-
fied the latter and found that costs are incurred for both 
transport and services, despite malaria care in The Gam-
bia being provided free-of-charge and VHWs being avail-
able in most villages. To reduce malaria transmission in 
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areas with a high coverage of prevention interventions, 
novel approaches such as mass drug administration with 
ivermectin are needed. This study can add to the evi-
dence base that is needed to establish the cost-effective-
ness of such approaches for regular use or for malaria 
elimination. Apart from clinical and costing data, cost-
effectiveness studies and policy should take into account 
health system barriers and local cultural interpretations 
of disease that may prevent theoretically efficacious 
interventions from reaching their full potential for vul-
nerable populations.
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